Back Bay
Read more
Creation House
Creation House
Funding
Convertible loan of 1,3M euros (10M DKK)
Purpose
Maturation of project to attract funding
Eligibility
Established proof of concept and initial business plan
Key Outcome
A prototype or lead candidate
Duration
18 months
Location
BioInnovation Institute in Copenhagen, Denmark
Approvers
The BII board of directors
Open Calls
Up to eight loans granted per open call
FUNDING
Convertible loan of 1,3M euros (10M DKK)
PURPOSE
Maturation of project to attract funding
ELIGIBILITY
Established proof of concept and initial business plan
KEY OUTCOME
A prototype or lead candidate
DURATION
18 months
LOCATION
BioInnovation Institute in Copenhagen, Denmark
APPROVERS
The BII board of directors
OPEN CALLS
Up to eight loans granted per open call
The Creation House program
Creation House is for companies with a solid, initial business plan. The therapeutics area requires a cellular proof of concept with chemical or biological tool compounds. Bioindustrials requires a proof of concept on MVP, and health tech requires a scale-up ready MVP.
In collaboration with the BII team and our network of experts, you will make a gap analysis for your start-up to find weak spots and roll out a detailed development plan to reach the milestones concerning drug development, good manufacturing practice, regulatory strategy, etc. The purpose of the 18-month program is to build a case that can attract substantial funding. BII will fund up to seven companies in the program with a risk-free convertible loan of EUR 1.3M.
Check out our frequently asked questions and read the program guidelines here
Call opens
October 6, 2021
Deadline
November 25, 2021 at 14.00 CEST
Pitch day for invited applicants
February 22-24, 2022
Applicant notification
Mid-March, 2022
Start date
June 1, 2022
Creation House Journey
Frederik Petursson Madsen
CEO, Cirqle BioMedical
“Becoming part of BioInnovation Institute has made a really big difference. They have managed to build a bridge that has lacked between research and venture capital. It has helped us attract talented people and put in place a solid plan that we are now executing, so we can create a new paradigm in contraception.”
Bo Tandrup
CEO, Lophora
“BII is the perfect platform for start-up companies in the life science field. During my +20 years in the industry I have founded and co-founded 6 companies, but I have never before had the level of support offered by BII. It’s not only access to seed capital, highly professional guidance in writing a business plan, and an outstanding global network for attracting funding; BII also offers office and lab facilities, legal advice, support with accounting and top-notch gourmet coffee.”
Ian Laquian
CEO and Co-founder, Kariya Pharma
“Our experiences and learnings from BII are less technical in nature, but rather denote the importance of community and (physical) proximity to innovators and facilitators. The BII provides us a world-class workspace to work from, where ideas and experiences are easily shared amongst like-minded entrepreneurs and industry experienced BII staff members. In our particular case, we are flanked by a number of CNS focused therapeutics companies that are all pretty much at the same stage of development. Hence, domain expertise, talent, experience, and support are always just meters away. This has helped us avoid reinventing the wheel many times over. Kariya is on the verge of initiating our regulatory toxicology studies, which is the final preclinical hurdle before going into human studies. “
Ph.D. Claus Elsborg Olesen
CEO, STipe Therapeutics
“Being a part of the BII creation house program has enabled STipe to recruit scientists with the diverse skills that have been essential for the further development of our leading technology for immune-oncology. While the BII team itself has helped us to establish and build relationships within the local and global biotech communities, culminating in a successful Series A round last October. Thanks to the BII we remain on track to deliver a first clinical candidate.”
Meet the Creation House team
Start-ups we work with
Program partners
When joining the BII programs, start-ups become part of an international community focused on bringing ideas to life and science to the market.
In collaboration with our partners, we want to create value for the companies in BII’s programs and our ecosystem. Our program advisory group and financing (VC) partnerships are focused on improving the likelihood of successful exits for our start-ups. The program advisory group of internationally-oriented VC companies advises BII in the selection of start-ups for our programs.
Meet our partners below and click on the read more button to learn more about what they offer start-ups in BII’s community.
Program collaborations
Back Bay’s expert guidance to companies at the earliest stages nourishes insight into the most promising science and technologies in development. They couple this with an exceptional understanding of development strategies globally, resulting in a true partnership for every stage of development.
Back Bay advisors and bankers bring their unique perspectives through landscape analyses and patient journeys, inflection points, capital raise planning, partnering, exit strategies, and more. They can help figure out what to do and then get it done.
Coulter Partners is a board and senior-level executive search specialist focused exclusively on global Life Sciences. From their offices in the UK, Europe, North America, and Asia-Pacific, they work together across boundaries and disciplines to build outstanding leadership teams for their clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, health tech, CRO, and services sectors. Their industry-leading reputation is founded on deep sector knowledge and innovative thinking. Their strategy is built on unique team culture and truly global reach.
“Our goal is to bring you the world’s best talent.”
Innovayt helps BII start-ups and researchers obtain funding for their projects through high-quality grant and funding applications. Innovayt offers a broad range of services, including identification and selection of funding opportunities; preparation and writing of effective funding applications; assistance for project management after approval; and training and public speaking related to innovation and finance. In their work with innovation funding, Innovayt can assist BII start-ups throughout all phases of projects, from ideation through application and submission to project management.
Plesner Law Firm is a contributing partner in the BII network and offers the BII start-ups free legal advice and expertise to avoid the many legal pitfalls that entrepreneurs face when starting a business. As part of the partnership, two lawyers from Plesner are present one day a week at the BII offices, where they will provide consultancy and legal guidance.
Zacco is a full-service intellectual property consultancy and contributing partner in the BII network. Zacco offers BII start-ups free advice and expertise on intellectual property rights to avoid legal pitfalls and to strengthen their position when looking for investors or cooperation partners.
Program Advisory Group - Therapeutics
Abingworth is a leading transatlantic life science investment firm. They help transform cutting-edge science into novel medicines by providing capital and expertise to top-caliber management teams building world-class companies.
Since 1973, Abingworth has invested in 168 life science companies, leading to 44 M&As and 69 IPOs. Their therapeutic-focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development.
Novo Seeds is the early-stage investment arm of Novo Holdings. Novo Holdings is a leading international life science investor focusing on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Sofinnova Partners is a leading European venture capital firm specializing in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from Europe, the U.S., and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals in the US and UK have experience spanning basic science, drug development, and commercialization. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. In its 30+ year history, SR One has invested >$1.1 billion in nearly 190 companies, and its current portfolio includes 40+ private and public investments.
Program Advisory Group - BioIndustrials
Founded in 2007, Redalpine is a leading European early-stage venture capital investment company, currently managing six venture funds. Redalpine has a sector-agnostic focus, and the diverse team supports more than 70 portfolio companies financially and with its in-house operational and subject matter expertise and extensive international network. Redalpine aims to help talented entrepreneurs turn their visions into reality and scale their businesses into global success stories. Redalpine is based in Zurich, Switzerland.
Wellington Partners is a leading European Venture Capital firm investing in early – and growth-stage life science companies. Wellington Partners focuses on investing in the most promising life science companies in biotechnology, therapeutics, medical technology, diagnostics, and digital health. With funds totaling EUR 1 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world-class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in more than 40 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Themis (acquired by MSD), Immatics and AMBOSS.
Novo Seeds is the early-stage investment arm of Novo Holdings. Novo Holdings is a leading international life science investor focusing on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Sofinnova Partners is a leading European venture capital firm specializing in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from Europe, the U.S., and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
The March Fund (“TMF”) – Technology. Food. Health. TMF is a technology venture capital fund dedicated to the transformation of the multi-trillion-dollar food industry and the expanding global health opportunity this represents. Our focus is on breakthrough technologies and defensible intellectual assets that can be rapidly commercialized and scaled to create healthier and more affordable nutrition solutions.
The Founding Partners are Harold Schmitz Ph.D. (Senior Scholar at the Graduate School of Management, University of California, Davis; Life Member of the Council on Foreign Relations, and former Chief Science Officer at Mars, Incorporated), and Christopher Lai (former Director at Horizons Ventures and former Co-Chairman of Celsius Holdings NASDAQ:CELH).
They have established unique collaborations with a world-class network of universities, companies, researchers, innovators, and industry experts. TMF has unparalleled access to the most exciting technologies, early-stage companies, and founders defining the role of food in the new economy of health.
Program Advisory Group - Health Tech
Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutic areas.
Sound Bioventures Fund I AB is a registered alternative investment fund under the Swedish Alternative Investment Funds Managers Act. The target size for the fund is EUR 150 million.
Novo Seeds is the early-stage investment arm of Novo Holdings. Novo Holdings is a leading international life science investor focusing on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Sofinnova Partners is a leading European venture capital firm specializing in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from Europe, the U.S., and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
BioVentures MedTech Funds invests in leading-edge medical technologies. Founded by the highly experienced team of BioVentures Investors, BioVentures MedTech Growth Capital Fund and BioVentures MedTech Innovation Fund target companies that develop next-generation implantable and disposable devices, diagnostics, imaging, and digital health.
Program Advisory Group Experts
SG
Shomit Ghose
Venture Capitalist & Entrepreneur
HealthTech
EA
Eric Alan Rapp
Partner at VF Venture
BioIndustrials
CN
Chris Newton
Independant consultant
Therapeutics
JS
John Shields
Non Executive Director at Adaptate Biotherapeutics & Microbiotica Ltd.
Therapeutics
CJ
Christel Jørgensen
Consultant, Bactolife ApS
BioIndustrials
PG
Pam Garside
Management Consultant, Newhealth
HealthTech
Contact
Reach out to Senior Scientific Business Developer Hervør Lykke Olsen if you want to know more about the Creation House program.
Incubation environments
Inspired by successful incubation environments from around the world, BII offers your team incubation in our Copenhagen facilities. Here you will be surrounded by like-minded researchers and entrepreneurs working on their projects in the open and collaborative environment at BII. In your daily work, your team will also have access to the capacities of the BII team, mentors, experts, and our global network. We offer state-of-the-art facilities in open office space and open labs to meet your projects’ needs at desirable rates, which are covered by founder-friendly convertible loans.
BII sits in the heart of the Copenhagen Science City near life-science research institutions and start-up hubs.
Any questions? Read more in our FAQ section.
Stay up to date by signing up for our newsletter.
